Jump to content

ABT-202

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by JCW-CleanerBot (talk | contribs) at 23:36, 6 November 2017 (task, replaced: Current opinion in investigational drugs (London, England : 2000) → Current Opinion in Investigational Drugs using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

ABT-202
Identifiers
  • (R)-1-(Pyridin-3-yl)pyrrolidin-3-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC9H13N3
Molar mass163.219 g·mol−1
3D model (JSmol)
  • N[C@@H]1CCN(C2=CC=CN=C2)C1
  • InChI=1S/C9H13N3/c10-8-3-5-12(7-8)9-2-1-4-11-6-9/h1-2,4,6,8H,3,5,7,10H2/t8-/m1/s1 ☒N
  • Key:LVGMMVAWLISWJD-MRVPVSSYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

ABT-202 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors and has been researched for use as an analgesic, although it has not passed clinical trials.[1][2][3]

References

  1. ^ Jain, K. K. (2004). "Modulators of nicotinic acetylcholine receptors as analgesics". Current Opinion in Investigational Drugs. 5 (1): 76–81. PMID 14983978.
  2. ^ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–767. doi:10.1002/cmdc.200600207. PMID 17295372.
  3. ^ Xu, Naxing; Kim, Grace E.; Gregg, Hope; Wagdy, Azza; Swaine, Brendan A.; Chang, Min S.; El-Shourbagy, Tawakol A. (September 2004). "Automated 96-well liquid–liquid back extraction liquid chromatography–tandem mass spectrometry method for the determination of ABT-202 in human plasma". Journal of Pharmaceutical and Biomedical Analysis. 36 (1): 189–195. doi:10.1016/j.jpba.2004.05.013.